The true center of your DX stack isn’t a system. It’s the screen where your customer experiences what you built. That’s where ...

The words that make up your compliance program documents are critical, there’s no doubt about that. But they will only ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.